Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, and RSV-ARI. We evaluated efficacy and immunogenicity among participants with coexisting cardiorespiratory or endocrine/metabolic conditions that increase the risk of severe RSV disease ("conditions of interest").
METHODS: Medically stable ≥60-year-old participants received 1 dose of RSVPreF3 OA or placebo. Efficacy against first RSV-LRTD and RSV-ARI episodes was assessed in subgroups with/without coexisting cardiorespiratory or endocrine/metabolic conditions of interest. Immunogenicity was analyzed post hoc in these subgroups.
RESULTS: In total, 12 467 participants received RSVPreF3 OA and 12 499 received placebo. Of these, 39.6% (RSVPreF3 OA) and 38.9% (placebo) had ≥1 coexisting condition of interest. The median efficacy follow-up was 6.7 months. Efficacy against RSV-LRTD was high in participants with ≥1 condition of interest (94.6%), ≥1 cardiorespiratory (92.1%), ≥1 endocrine/metabolic (100%), and ≥2 conditions of interest (92.0%). Efficacy against RSV-ARI was 81.0% in participants with ≥1 condition of interest (88.1% for cardiorespiratory, 79.4% for endocrine/metabolic conditions) and 88.0% in participants with ≥2 conditions of interest. Postvaccination neutralizing titers were at least as high in participants with ≥1 condition of interest as in those without.
CONCLUSIONS: RSVPreF3 OA was efficacious against RSV-LRTD and RSV-ARI in older adults with coexisting medical conditions associated with an increased risk of severe RSV disease.
CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT04886596.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 78(2024), 1 vom: 25. Jan., Seite 202-209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feldman, Robert G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.03.2024 published: Print ClinicalTrials.gov: NCT04886596 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361957602 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361957602 | ||
| 003 | DE-627 | ||
| 005 | 20240331000655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM361957602 | ||
| 035 | |a (NLM)37698366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feldman, Robert G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04886596 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, and RSV-ARI. We evaluated efficacy and immunogenicity among participants with coexisting cardiorespiratory or endocrine/metabolic conditions that increase the risk of severe RSV disease ("conditions of interest") | ||
| 520 | |a METHODS: Medically stable ≥60-year-old participants received 1 dose of RSVPreF3 OA or placebo. Efficacy against first RSV-LRTD and RSV-ARI episodes was assessed in subgroups with/without coexisting cardiorespiratory or endocrine/metabolic conditions of interest. Immunogenicity was analyzed post hoc in these subgroups | ||
| 520 | |a RESULTS: In total, 12 467 participants received RSVPreF3 OA and 12 499 received placebo. Of these, 39.6% (RSVPreF3 OA) and 38.9% (placebo) had ≥1 coexisting condition of interest. The median efficacy follow-up was 6.7 months. Efficacy against RSV-LRTD was high in participants with ≥1 condition of interest (94.6%), ≥1 cardiorespiratory (92.1%), ≥1 endocrine/metabolic (100%), and ≥2 conditions of interest (92.0%). Efficacy against RSV-ARI was 81.0% in participants with ≥1 condition of interest (88.1% for cardiorespiratory, 79.4% for endocrine/metabolic conditions) and 88.0% in participants with ≥2 conditions of interest. Postvaccination neutralizing titers were at least as high in participants with ≥1 condition of interest as in those without | ||
| 520 | |a CONCLUSIONS: RSVPreF3 OA was efficacious against RSV-LRTD and RSV-ARI in older adults with coexisting medical conditions associated with an increased risk of severe RSV disease | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT04886596 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a cardiorespiratory | |
| 650 | 4 | |a comorbidity | |
| 650 | 4 | |a respiratory tract illness | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Respiratory Syncytial Virus Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Antonelli-Incalzi, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Steenackers, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Dong-Gun |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ison, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Fissette, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a David, Marie-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Maréchal, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Van der Wielen, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Kostanyan, Lusine |e verfasserin |4 aut | |
| 700 | 1 | |a Hulstrøm, Veronica |e verfasserin |4 aut | |
| 700 | 0 | |a AReSVi-006 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Mark |e investigator |4 oth | |
| 700 | 1 | |a Adams, Michael |e investigator |4 oth | |
| 700 | 1 | |a Akite, Elaine Jacqueline |e investigator |4 oth | |
| 700 | 1 | |a Alt, Ingrid |e investigator |4 oth | |
| 700 | 1 | |a Andrews, Charles |e investigator |4 oth | |
| 700 | 1 | |a Asatryan, Asmik |e investigator |4 oth | |
| 700 | 1 | |a Athan, Eugene |e investigator |4 oth | |
| 700 | 1 | |a Bahrami, Ghazaleh |e investigator |4 oth | |
| 700 | 1 | |a Bargagli, Elena |e investigator |4 oth | |
| 700 | 1 | |a Bhorat, Qasim |e investigator |4 oth | |
| 700 | 1 | |a Bird, Paul |e investigator |4 oth | |
| 700 | 1 | |a Borowy, Przemyslaw |e investigator |4 oth | |
| 700 | 1 | |a Boutry, Celine |e investigator |4 oth | |
| 700 | 1 | |a Brotons Cuixart, Carles |e investigator |4 oth | |
| 700 | 1 | |a Browder, David |e investigator |4 oth | |
| 700 | 1 | |a Brown, Judith |e investigator |4 oth | |
| 700 | 1 | |a Buntinx, Erik |e investigator |4 oth | |
| 700 | 1 | |a Cameron, Donald |e investigator |4 oth | |
| 700 | 1 | |a Campora, Laura |e investigator |4 oth | |
| 700 | 1 | |a Chinsky, Kenneth |e investigator |4 oth | |
| 700 | 1 | |a Choi, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Choo, Eun-Ju |e investigator |4 oth | |
| 700 | 1 | |a Collete, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Corral Carrillo, Maria |e investigator |4 oth | |
| 700 | 1 | |a Davis, Matthew G |e investigator |4 oth | |
| 700 | 1 | |a de Heusch, Magali |e investigator |4 oth | |
| 700 | 1 | |a de Looze, Ferdinandus |e investigator |4 oth | |
| 700 | 1 | |a De Meulemeester, Marc |e investigator |4 oth | |
| 700 | 1 | |a De Negri, Ferdinando |e investigator |4 oth | |
| 700 | 1 | |a De Schrevel, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a DeAtkine, David |e investigator |4 oth | |
| 700 | 1 | |a Dedkova, Viktoriya |e investigator |4 oth | |
| 700 | 1 | |a Descamps, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Dezutter, Nancy |e investigator |4 oth | |
| 700 | 1 | |a Dzongowski, Peter |e investigator |4 oth | |
| 700 | 1 | |a Eckermann, Tamara |e investigator |4 oth | |
| 700 | 1 | |a Essink, Brandon |e investigator |4 oth | |
| 700 | 1 | |a Faulkner, Karen |e investigator |4 oth | |
| 700 | 1 | |a Ferguson, Murdo |e investigator |4 oth | |
| 700 | 1 | |a Fuller, Gregory |e investigator |4 oth | |
| 700 | 1 | |a Galan Melendez, Isabel Maria |e investigator |4 oth | |
| 700 | 1 | |a Gentile, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Ghesquiere, Wayne |e investigator |4 oth | |
| 700 | 1 | |a Grimard, Doria |e investigator |4 oth | |
| 700 | 1 | |a Gruselle, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Halperin, Scott |e investigator |4 oth | |
| 700 | 1 | |a Heer, Amardeep |e investigator |4 oth | |
| 700 | 1 | |a Helman, Laura |e investigator |4 oth | |
| 700 | 1 | |a Hotermans, Andre |e investigator |4 oth | |
| 700 | 1 | |a Jelinek, Tomas |e investigator |4 oth | |
| 700 | 1 | |a Kamerbeek, Jackie |e investigator |4 oth | |
| 700 | 1 | |a Kim, Hyo Youl |e investigator |4 oth | |
| 700 | 1 | |a Kimmel, Murray |e investigator |4 oth | |
| 700 | 1 | |a Koch, Mark |e investigator |4 oth | |
| 700 | 1 | |a Kokko, Satu |e investigator |4 oth | |
| 700 | 1 | |a Koski, Susanna |e investigator |4 oth | |
| 700 | 1 | |a Kotb, Shady |e investigator |4 oth | |
| 700 | 1 | |a Lalueza, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Langley, Joanne M |e investigator |4 oth | |
| 700 | 1 | |a Lee, Jin-Soo |e investigator |4 oth | |
| 700 | 1 | |a Leroux-Roels, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Lins, Muriel |e investigator |4 oth | |
| 700 | 1 | |a Lombaard, Johannes |e investigator |4 oth | |
| 700 | 1 | |a Mahomed, Akbar |e investigator |4 oth | |
| 700 | 1 | |a Malerba, Mario |e investigator |4 oth | |
| 700 | 1 | |a Marechal, Celine |e investigator |4 oth | |
| 700 | 1 | |a Martinon-Torres, Federico |e investigator |4 oth | |
| 700 | 1 | |a Martinot, Jean-Benoit |e investigator |4 oth | |
| 700 | 1 | |a Masuet-Aumatell, Cristina |e investigator |4 oth | |
| 700 | 1 | |a McNally, Damien |e investigator |4 oth | |
| 700 | 1 | |a Medina Pech, Carlos Eduardo |e investigator |4 oth | |
| 700 | 1 | |a Mendez Galvan, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Mesaros, Narcisa Elena |e investigator |4 oth | |
| 700 | 1 | |a Mesotten, Dieter |e investigator |4 oth | |
| 700 | 1 | |a Mitha, Essack |e investigator |4 oth | |
| 700 | 1 | |a Mngadi, Kathryn |e investigator |4 oth | |
| 700 | 1 | |a Moeckesch, Beate |e investigator |4 oth | |
| 700 | 1 | |a Montgomery, Barnaby |e investigator |4 oth | |
| 700 | 1 | |a Murray, Linda |e investigator |4 oth | |
| 700 | 1 | |a Nally, Rhiannon |e investigator |4 oth | |
| 700 | 1 | |a Narejos Perez, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Newberg, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Nugent, Paul |e investigator |4 oth | |
| 700 | 1 | |a Ochoa Mazarro, Dolores |e investigator |4 oth | |
| 700 | 1 | |a Oda, Harunori |e investigator |4 oth | |
| 700 | 1 | |a Olivier, Aurelie |e investigator |4 oth | |
| 700 | 1 | |a Orso, Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Ortiz Molina, Jacinto |e investigator |4 oth | |
| 700 | 1 | |a Pak, Tatiana |e investigator |4 oth | |
| 700 | 1 | |a Park, Dae Won |e investigator |4 oth | |
| 700 | 1 | |a Patel, Meenakshi |e investigator |4 oth | |
| 700 | 1 | |a Patel, Minesh |e investigator |4 oth | |
| 700 | 1 | |a Pedro Pijoan, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Perez Vera, Merce |e investigator |4 oth | |
| 700 | 1 | |a Perez, Alberto Borobia |e investigator |4 oth | |
| 700 | 1 | |a Perez-Breva, Lina |e investigator |4 oth | |
| 700 | 1 | |a Pileggi, Claudia |e investigator |4 oth | |
| 700 | 1 | |a Pregliasco, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Pretswell, Carol |e investigator |4 oth | |
| 700 | 1 | |a Quinn, Dean |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 78(2024), 1 vom: 25. Jan., Seite 202-209 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2024 |g number:1 |g day:25 |g month:01 |g pages:202-209 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2024 |e 1 |b 25 |c 01 |h 202-209 | ||